Swiss healthcare giant Roche posted a 7% year-over-year increase in group sales at constant exchange rates for the first half of 2025, reaching CHF 30.9 billion, according to the company’s latest financial statement. On a Swiss franc basis, growth stood at 4%.
The surge was primarily fueled by rising demand for innovative pharmaceuticals, particularly treatments targeting breast cancer, severe eye diseases, hemophilia A, and multiple sclerosis. Roche’s Pharmaceuticals Division saw a 10% increase in sales, climbing to CHF 24 billion — contributing CHF 1.7 billion in additional sales compared to the same period in 2024.
The Diagnostics Division, meanwhile, recorded sales of CHF 6.95 billion, maintaining its performance from last year. Strong demand for pathology solutions and blood screening tests helped offset the impact of healthcare pricing reforms in China.
CEO Highlights Pipeline Progress
Commenting on the results, Roche Group CEO Thomas Schinecker emphasized the company’s sustained growth momentum, stating:
“We’ve made significant progress in our portfolio over the past six months, advancing four potential therapies to the final stage of clinical development. These include innovative solutions in blood disorders, neurological diseases, and antibiotic resistance.”
Schinecker reiterated the company’s confidence in its innovation-led strategy:
“We are fully confident in continuing our strong performance thanks to our product portfolio and cutting-edge solutions. These strong results reinforce our outlook for the remainder of the year.”
Roche’s positive performance in H1 2025 reflects its strategic focus on high-need therapeutic areas and long-term investment in R&D, setting a robust foundation for the full-year outlook.
Source: Anadolu Ajansı/ Prepared by: İlayda Gök